| نویسنده | نفر چندم مقاله |
|---|---|
| علیرضا خبازی اسکویی | دوم |
| مهرزاد حاج علیلوی بناب | سوم |
| سیدصدرالدین راثی هاشمی | چهارم |
| آیدا مالک مهدوی | پنجم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Aim: Proliferative lupus nephritis is a common and severe manifestation of systemic lupus erythematosus (SLE) that can lead to end stage renal disease and death. The aim of this study was to evaluate the long-term efficacy of cyclosporine A (CSA) in the treatment of refractory proliferative lupus nephritis. Methods: In a retrospective study patients with mycophenolate mofetil and/or cyclophosphamide resistant proliferative lupus nephritis under treatment with CSA were entered to the study. They were evaluated according to the reduction in proteinuria, creatinine clearance, remission of the renal disease, SLE disease activity index (SLEDAI), reduction in prednisolone dose, mortality and side effects of treatment. Results: Twenty-five patients with biopsy proven proliferative lupus nephritis with mean age of 30±6.9 years including 5 men (20%) and 20 women (80%) were studied. The follow-up duration was 27.1±17.6 months. Proteinuria was decreased significantly during the treatment with CSA (p<0.001). Creatinine clearance was stable and changes was not significant. Complete renal remission and partial renal remission was occurred in 60% and 32% of patients respectively. Prednisolone dose was reduced from 26.3 mg/d before treatment to 6.8 mg/d after treatment with CSA (P=0.001). No end-stage renal disease or mortality were happened. The most common adverse events were dyspepsia. Conclusion: According to the results of our study CSA is effective and safe in the treatment of refractory proliferative lupus nephritis. |
| کلمات کلیدی | : Cyclosporine A, treatment, Refractory Proliferative Lupus Nephritis |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| IMG_0001.jpg | 1395/08/01 | 1009513 | دانلود |
| Invitation CSA.pdf | 1395/08/01 | 126912 | دانلود |